Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03866460 · ClinicalTrials.gov registry record
Determining Whether Intra-Arterial Carboplatin Causes Hearing Loss in Children
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 30
- Enrollment target
NCT03866460: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03866460 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03866460 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to find out how often hearing loss occurs in patients with retinoblastoma after receiving treatment with intra-arterial carboplatin.
Interventions
- DIAGNOSTIC_TEST Distortion product otoacoustic emission measurement (DPOAE)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-03-06 |
| Est. Completion | 2024-11-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03866460
The ClinicalTrials.gov registry entry for NCT03866460 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Distortion product otoacoustic emission measurement (DPOAE) is the first listed.
NCT03866460 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03866460 about?
NCT03866460 is a clinical study titled "Determining Whether Intra-Arterial Carboplatin Causes Hearing Loss in Children". The purpose of this study is to find out how often hearing loss occurs in patients with retinoblastoma after receiving treatment with intra-arterial carboplatin.
What is the current status of trial NCT03866460?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2019-03-06. Estimated completion is 2024-11-04.
What interventions are being tested in trial NCT03866460?
The interventions under investigation include: Distortion product otoacoustic emission measurement (DPOAE) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03866460?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.